JP2020500837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500837A5 JP2020500837A5 JP2019517034A JP2019517034A JP2020500837A5 JP 2020500837 A5 JP2020500837 A5 JP 2020500837A5 JP 2019517034 A JP2019517034 A JP 2019517034A JP 2019517034 A JP2019517034 A JP 2019517034A JP 2020500837 A5 JP2020500837 A5 JP 2020500837A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- assembled
- hcv
- order
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903961 | 2016-09-29 | ||
| AU2016903961A AU2016903961A0 (en) | 2016-09-29 | Refolded glycoproteins for vaccine production | |
| PCT/AU2017/051037 WO2018058177A1 (en) | 2016-09-29 | 2017-09-22 | Assembled glycoproteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500837A JP2020500837A (ja) | 2020-01-16 |
| JP2020500837A5 true JP2020500837A5 (https=) | 2021-04-30 |
| JP7068284B2 JP7068284B2 (ja) | 2022-05-16 |
Family
ID=61762303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517034A Active JP7068284B2 (ja) | 2016-09-29 | 2017-09-22 | アセンブルした糖タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12162906B2 (https=) |
| EP (1) | EP3519424A4 (https=) |
| JP (1) | JP7068284B2 (https=) |
| KR (2) | KR20240122578A (https=) |
| CN (1) | CN110049993A (https=) |
| AU (1) | AU2017334263B2 (https=) |
| IL (1) | IL265524B2 (https=) |
| WO (1) | WO2018058177A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4149541A4 (en) * | 2020-05-11 | 2024-06-05 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | NUCLEIC ACID-BASED HEPATITIS C VACCINE COMPRISING A VARIABLE-DOMAIN-DELETED E2 POLYPEPTIDE |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| CN115389681B (zh) * | 2022-11-01 | 2023-01-20 | 常州百瑞吉生物医药有限公司 | 一种巯基化透明质酸衍生物中二硫苏糖醇残留的检测方法 |
| WO2025231336A1 (en) * | 2024-05-02 | 2025-11-06 | Avista Therapeutics, Inc. | Adeno-associated virus vectors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9506059A (pt) * | 1994-07-29 | 1997-10-28 | Innogenetics Nv | Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico |
| EP1463521A4 (en) * | 2001-12-17 | 2009-06-24 | Us Gov Health & Human Serv | INHIBITOR OF GP41 |
| KR20040076869A (ko) * | 2001-12-18 | 2004-09-03 | 인노제네틱스 엔. 브이. | 진단적 및 치료적 용도를 위한 정제된 ｃ형 간염 바이러스외피 단백질 |
| JP5674310B2 (ja) * | 2006-08-25 | 2015-02-25 | ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド | 組換えｈｃｖ ｅ２糖タンパク質 |
| WO2012016290A1 (en) * | 2010-08-04 | 2012-02-09 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Modified hepatitis c virus proteins |
| CN104324373B (zh) * | 2010-11-26 | 2018-10-09 | 麦克法兰博尼特医学健康研究公司 | 组合物及其制备方法 |
-
2017
- 2017-09-22 KR KR1020247025714A patent/KR20240122578A/ko active Pending
- 2017-09-22 WO PCT/AU2017/051037 patent/WO2018058177A1/en not_active Ceased
- 2017-09-22 CN CN201780063166.XA patent/CN110049993A/zh active Pending
- 2017-09-22 EP EP17854239.5A patent/EP3519424A4/en active Pending
- 2017-09-22 KR KR1020197011934A patent/KR20190078574A/ko active Pending
- 2017-09-22 JP JP2019517034A patent/JP7068284B2/ja active Active
- 2017-09-22 AU AU2017334263A patent/AU2017334263B2/en active Active
- 2017-09-22 US US16/337,900 patent/US12162906B2/en active Active
-
2019
- 2019-03-20 IL IL265524A patent/IL265524B2/en unknown
-
2024
- 2024-12-09 US US18/974,404 patent/US20250215048A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yong et al. | Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus | |
| AU2012269907B2 (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
| US12600752B2 (en) | Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development | |
| CN108912215A (zh) | 用于登革病毒表位的方法和组合物 | |
| JP2012503011A5 (ja) | 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物 | |
| Merino-Ramos et al. | Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus | |
| US10870682B2 (en) | Methods and compositions for dengue virus vaccines | |
| JP2020500837A5 (https=) | ||
| US10398768B2 (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| Baehner et al. | Vaccines against norovirus: state of the art trials in children and adults | |
| HK1206366A1 (en) | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes | |
| Fan et al. | Genotype I of Japanese encephalitis virus virus-like particles elicit sterilizing immunity against genotype I and III viral challenge in swine | |
| JP7545955B2 (ja) | インフルエンザｈａスプリットワクチンの製造方法 | |
| JP2020536107A5 (https=) | ||
| Galula et al. | Cross-reactivity reduced dengue virus serotype 2 vaccine does not confer cross-protection against other serotypes of dengue viruses | |
| Camus | Development and characterization of Lassa virus vaccines and mouse model | |
| Willis | The Effect of Maternal Antibodies on Anti-viral Immunity in Infant Mice | |
| Deng et al. | Characterization of a novel neutralizing monoclonal antibody that recognizes the fusion loop of Flavivirus envelope protein | |
| Caine | Understanding host adaptation and disease progression of enterovirus 71 using mouse models, reverse genetics, and in vivo imaging | |
| WO2015133467A1 (ja) | Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質 |